These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30573026)

  • 21. Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Bansal N; Zelnick LR; Soliman EZ; Anderson A; Christenson R; DeFilippi C; Deo R; Feldman HI; He J; Ky B; Kusek J; Lash J; Seliger S; Shafi T; Wolf M; Go AS; Shlipak MG;
    Am J Kidney Dis; 2021 Jun; 77(6):907-919. PubMed ID: 33309861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal function largely influences Galectin-3 prognostic value in heart failure.
    Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
    Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease.
    Maiolino G; Rossitto G; Pedon L; Cesari M; Frigo AC; Azzolini M; Plebani M; Rossi GP
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):725-32. PubMed ID: 25614283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve.
    Holmager P; Egstrup M; Gustafsson I; Schou M; Dahl JS; Rasmussen LM; Møller JE; Tuxen C; Faber J; Kistorp C
    BMC Cardiovasc Disord; 2017 Jan; 17(1):22. PubMed ID: 28068900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults.
    deFilippi CR; de Lemos JA; Christenson RH; Gottdiener JS; Kop WJ; Zhan M; Seliger SL
    JAMA; 2010 Dec; 304(22):2494-502. PubMed ID: 21078811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study.
    Haring R; Enserro D; Xanthakis V; Mitchell GF; Benjamin EJ; Hamburg NM; Sullivan L; Nauck M; Wallaschofski H; Vasan RS
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27385427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction.
    Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Balsam P; Opolski G; Filipiak KJ
    Dis Markers; 2019; 2019():9529053. PubMed ID: 31687050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galectin-3 as a candidate upstream biomarker for quantifying risks of myocardial ageing.
    Keng BMH; Gao F; Ewe SH; Tan RS; Teo LLY; Xie BQ; Koh WP; Koh AS
    ESC Heart Fail; 2019 Oct; 6(5):1068-1076. PubMed ID: 31392851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Galectin-3 and risk of ischaemic stroke: Reasons for Geographic and Racial Differences in Stroke cohort.
    Arora P; Agarwal Z; Venkatraman A; Callas P; Kissela BM; Jenny NS; Judd SE; Zakai NA; Cushman M
    Eur J Neurol; 2017 Dec; 24(12):1464-1470. PubMed ID: 28872212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.
    Lok DJ; Lok SI; Bruggink-André de la Porte PW; Badings E; Lipsic E; van Wijngaarden J; de Boer RA; van Veldhuisen DJ; van der Meer P
    Clin Res Cardiol; 2013 Feb; 102(2):103-10. PubMed ID: 22886030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma galectin 3 and heart failure risk in the Physicians' Health Study.
    Djoussé L; Matsumoto C; Petrone A; Weir NL; Tsai MY; Gaziano JM
    Eur J Heart Fail; 2014 Mar; 16(3):350-4. PubMed ID: 24464746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population.
    Imran TF; Shin HJ; Mathenge N; Wang F; Kim B; Joseph J; Gaziano JM; Djoussé L
    Am J Cardiol; 2017 Jan; 119(1):57-64. PubMed ID: 28247849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study.
    Liu S; Wu Q; Zhang S; Wang Z; Liu H; Teng L; Xiao P; Lu Y; Wang X; Dong C; Xiao J; Zhang J
    BMC Nephrol; 2022 Jan; 23(1):5. PubMed ID: 34979958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Galectin-3 With Diabetes Mellitus in the Dallas Heart Study.
    Vora A; de Lemos JA; Ayers C; Grodin JL; Lingvay I
    J Clin Endocrinol Metab; 2019 Oct; 104(10):4449-4458. PubMed ID: 31162551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3.
    Zivlas C; Triposkiadis F; Psarras S; Giamouzis G; Skoularigis I; Chryssanthopoulos S; Kapelouzou A; Ramcharitar S; Barnes E; Papasteriadis E; Cokkinos D
    Ther Adv Cardiovasc Dis; 2017 Nov; 11(11):283-295. PubMed ID: 28830298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies.
    Drechsler C; Delgado G; Wanner C; Blouin K; Pilz S; Tomaschitz A; Kleber ME; Dressel A; Willmes C; Krane V; Krämer BK; März W; Ritz E; van Gilst WH; van der Harst P; de Boer RA
    J Am Soc Nephrol; 2015 Sep; 26(9):2213-21. PubMed ID: 25568176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating Galectin-3 Following Heart Transplant: Long-term Dynamics and Prognostic Value.
    Suárez-Fuentetaja N; Barge-Caballero E; Bayés-Genís A; Doménech N; Moreda-Santamaría L; Paniagua-Martín MJ; Barge-Caballero G; Couto-Mallón D; Solla-Buceta M; Estévez-Cid F; Cuenca-Castillo JJ; Pombo-Otero J; Grille-Cancela Z; Blanco-Canosa P; Muñiz J; Vázquez-Rodríguez JM; Crespo-Leiro MG
    Rev Esp Cardiol (Engl Ed); 2019 Nov; 72(11):899-906. PubMed ID: 30477951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience.
    Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D
    Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study.
    Bansal N; Zelnick L; Go A; Anderson A; Christenson R; Deo R; Defilippi C; Lash J; He J; Ky B; Seliger S; Soliman E; Shlipak M; ;
    J Am Heart Assoc; 2019 Nov; 8(21):e012336. PubMed ID: 31645163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists.
    Koukoui F; Desmoulin F; Galinier M; Barutaut M; Caubère C; Evaristi MF; Murat G; De Boer R; Berry M; Smih F; Rouet P
    PLoS One; 2015; 10(3):e0119160. PubMed ID: 25786035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.